W Busse

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Safety and efficacy of the prostaglandin D(2) receptor antagonist AMG 853 in asthmatic patients
    William W Busse
    Department of Medicine, University of Wisconsin, Madison, Wis Electronic address
    J Allergy Clin Immunol 131:339-45. 2013
  2. ncbi The brain and asthma: what are the linkages?
    William W Busse
    Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Chem Immunol Allergy 98:14-31. 2012
  3. ncbi Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
    Ashley Woodcock
    School of Translational Medicine, University of Manchester, Manchester, UK
    Respir Res 12:160. 2011
  4. ncbi Omalizumab and the risk of malignancy: results from a pooled analysis
    William Busse
    Department of Medicine, University of Wisconsin Medical School, Madison, WI, USA
    J Allergy Clin Immunol 129:983-9.e6. 2012
  5. ncbi Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses
    Ravi K Viswanathan
    Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Chest 141:1303-14. 2012
  6. ncbi Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
    Ashley Woodcock
    School of Translational Medicine, Manchester Academic Health Science Centre, University of Manchester, UK
    Respir Res 12:132. 2011
  7. ncbi Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study
    Martyn R Partridge
    Department of Respiratory Medicine, Faculty of Medicine, Imperial College London, London, UK
    BMC Pulm Med 6:13. 2006
  8. ncbi The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population
    James E Gern
    University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    BMC Pulm Med 9:17. 2009
  9. ncbi Role of viral respiratory infections in asthma and asthma exacerbations
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lancet 376:826-34. 2010
  10. ncbi The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: its measurement and clinical significance
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Chest 138:4S-10S. 2010

Research Grants

  1. Severe Asthma From Respiratory Infections
    William W Busse; Fiscal Year: 2010
  2. Severe Asthma From Respiratory Infections
    William Busse; Fiscal Year: 2005
  3. MECHANISMS OF RHINOVIRUS INDUCED ASTHMA
    William Busse; Fiscal Year: 2002
  4. Severe Asthma From Respiratory Infections
    William Busse; Fiscal Year: 2009

Detail Information

Publications97

  1. ncbi Safety and efficacy of the prostaglandin D(2) receptor antagonist AMG 853 in asthmatic patients
    William W Busse
    Department of Medicine, University of Wisconsin, Madison, Wis Electronic address
    J Allergy Clin Immunol 131:339-45. 2013
    ..AMG 853 is a potent, selective, orally bioavailable, small-molecule dual antagonist of human D-prostanoid and CRTH2...
  2. ncbi The brain and asthma: what are the linkages?
    William W Busse
    Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Chem Immunol Allergy 98:14-31. 2012
    ..Collectively, these data suggest that chronic stress enhances asthma severity through a number of novel mechanisms and the resulting increase in severity of asthma may not be responsiveness to standardly used treatments...
  3. ncbi Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
    Ashley Woodcock
    School of Translational Medicine, University of Manchester, Manchester, UK
    Respir Res 12:160. 2011
    ..The objectives of this study were to compare the efficacy and safety of once-daily (OD) evening and twice-daily (BD) regimens of the novel inhaled corticosteroid fluticasone furoate (FF) in asthma patients...
  4. ncbi Omalizumab and the risk of malignancy: results from a pooled analysis
    William Busse
    Department of Medicine, University of Wisconsin Medical School, Madison, WI, USA
    J Allergy Clin Immunol 129:983-9.e6. 2012
    ..5%) compared with control subjects (0.2%). The previous analysis was based on limited available data, warranting further investigation...
  5. ncbi Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses
    Ravi K Viswanathan
    Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Chest 141:1303-14. 2012
    ..Given the significant burden these allergic diseases impose on the health-care system, SIT appears to be a cost-effective adjunctive treatment in modifying the existing disease state...
  6. ncbi Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
    Ashley Woodcock
    School of Translational Medicine, Manchester Academic Health Science Centre, University of Manchester, UK
    Respir Res 12:132. 2011
    ....
  7. ncbi Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study
    Martyn R Partridge
    Department of Respiratory Medicine, Faculty of Medicine, Imperial College London, London, UK
    BMC Pulm Med 6:13. 2006
    ....
  8. ncbi The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population
    James E Gern
    University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    BMC Pulm Med 9:17. 2009
    ..This paper describes the study design, methods, and population of the Urban Environment and Childhood Asthma (URECA) study, which was established to investigate the immunologic causes of asthma among inner-city children...
  9. ncbi Role of viral respiratory infections in asthma and asthma exacerbations
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lancet 376:826-34. 2010
    ....
  10. ncbi The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: its measurement and clinical significance
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Chest 138:4S-10S. 2010
    ..Insight into how these interrelated components of AHR can contribute to asthma is gained by studying treatment effects and models of asthma provocation...
  11. ncbi A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis, USA
    J Allergy Clin Immunol 125:803-13. 2010
    ..Mepolizumab reduced airway and blood eosinophils and prevented asthma exacerbations. Thus, mepolizumab may be effective for long-term treatment of patients with selected eosinophilic disorders...
  12. ncbi The National Institutes of Allergy and Infectious Diseases networks on asthma in inner-city children: an approach to improved care
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis 53792, USA
    J Allergy Clin Immunol 125:529-37; quiz 538-9. 2010
    ....
  13. ncbi Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine
    William W Busse
    University of Wisconsin School of Medicine and Public Health, Madison, Wis, USA
    J Allergy Clin Immunol 127:130-7, 137.e1-3. 2011
    ..Asthma was the most common comorbidity of patients hospitalized with 2009 H1N1 influenza...
  14. ncbi Asthma exacerbations. 2: aetiology
    A M Singh
    Department of Medicine, Section of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin Medical School, Madison, Wisconsin, USA
    Thorax 61:809-16. 2006
    ..Through an understanding of underlying causes of asthma exacerbations, treatments with increased effectiveness may be developed, and it is these future developments that may directly influence the morbidity and mortality of the disease...
  15. ncbi Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy
    William Busse
    University of Wisconsin, Madison Medical School, Department of Medicine, 15 220 Clinical Science Center, 600 Highland Ave, Madison, WI 53792 2454, USA
    Chest 127:1312-26. 2005
    ..The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes...
  16. ncbi Addressing issues of asthma in inner-city children
    William W Busse
    University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Allergy Clin Immunol 119:43-9. 2007
    ....
  17. ncbi The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, J5 219 CSC, Box 2454, 600 Highland Ave, Madison, WI 53792, USA
    J Allergy Clin Immunol 121:1167-74. 2008
    ....
  18. ncbi Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients
    William W Busse
    University of Wisconsin Hospitals and Clinics, Madison, Wis 53792, USA
    J Allergy Clin Immunol 121:1407-14, 1414.e1-6. 2008
    ..The adjustable-dose budesonide/formoterol dry powder inhaler (DPI) has demonstrated similar or greater asthma control with less inhaled corticosteroid compared with the fixed-dose budesonide/formoterol DPI...
  19. ncbi Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial
    William W Busse
    Department of Medicine, Section of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Am J Respir Crit Care Med 178:1002-8. 2008
    ..The mechanism of action likely involves inhibition of proinflammatory cytokine generation by IL-2R blockade in activated T cells. Clinical trial registered with www.clinicaltrials.gov (NCT00028288)...
  20. ncbi Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity
    William W Busse
    Department of Medicine, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA
    Ann Allergy Asthma Immunol 96:60-8. 2006
    ..Montelukast has proven efficacy in the treatment of chronic asthma and seasonal allergic rhinitis, but it has not been evaluated in the subpopulation of asthmatic patients with seasonal asthma symptoms...
  21. ncbi Anti-immunoglobulin E for the treatment of allergic disease
    W Busse
    Department of Medicine, Allergy and Clinical Immunology Section, University of Wisconsin, Madison, Wisconsin 53792, USA
    Curr Opin Allergy Clin Immunol 1:105-8. 2001
    ..The following information will review recent experiences with anti-IgE and discuss the conditions in which this approach may be effective...
  22. ncbi Determinants of risk factors for asthma
    W W Busse
    University of Wisconsin Madison Medical School, Madison 53792 2454, USA
    Can Respir J 6:97-101. 1999
    ....
  23. ncbi Asthma diagnosis and treatment: filling in the information gaps
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Allergy Clin Immunol 128:740-50. 2011
    ..A major morbidity in asthmatic patients occurs with exacerbations and in patients with severe disease. Novel approaches to treatment for these conditions will be an important advance to reduce the morbidity associated with asthma...
  24. ncbi Anti-immunoglobulin E (omalizumab) therapy in allergic asthma
    W W Busse
    Department of Medicine, Allergy and Immunology Section, University of Wisconsin Medical School, Madison, Wisconsin, USA
    Am J Respir Crit Care Med 164:S12-7. 2001
    ..In addition, anti-IgE (omalizumab) has been shown to be safe and well tolerated...
  25. ncbi Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial
    William W Busse
    Department of Medicine, University of Wisconsin, K4 910 CSC, 600 Highland Avenue, Madison, WI 53792, USA
    Thorax 67:35-41. 2012
    ..FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease...
  26. ncbi Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children
    William W Busse
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53719, USA
    N Engl J Med 364:1005-15. 2011
    ..It has also revealed the limitations of environmental remediation and guidelines-based therapy in achieving greater disease control...
  27. ncbi Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial
    W Busse
    University of Wisconsin Hospital and Clinics, H6 367 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792 2454, USA
    J Fam Pract 50:595-602. 2001
    ..The objective of our study was to compare the efficacy and safety of fluticasone propionate (an inhaled corticosteroid) with zafirlukast (a leukotriene modifier) for persistent asthma...
  28. ncbi Mechanisms of asthma
    William W Busse
    Allergy and Clinical Immunology, University of Wisconsin Department of Medicine, Madison, WI, USA
    J Allergy Clin Immunol 111:S799-804. 2003
    ..The contribution of genetics to asthma has been examined in a wide variety of studies, ranging from epidemiologic association and twin studies all the way to molecular analysis through microarray gene expression experiments...
  29. ncbi Interferon-gamma enhances rhinovirus-induced RANTES secretion by airway epithelial cells
    Shinichi Konno
    Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
    Am J Respir Cell Mol Biol 26:594-601. 2002
    ..These findings suggest that IFN-gamma, by upregulating RANTES secretion, could be an important regulator of the initial immune response to rhinovirus infections...
  30. ncbi School examinations enhance airway inflammation to antigen challenge
    Lin Ying Liu
    Allergy and Immunology and Pulmonary and Critical Care Sections of the Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA
    Am J Respir Crit Care Med 165:1062-7. 2002
    ..Our findings suggest that stress associated with final examinations can act as a cofactor to increase eosinophilic airway inflammation to antigen challenge and thus may enhance asthma severity...
  31. ncbi Effects of inflammatory cytokines on the permeability of human lung microvascular endothelial cell monolayers and differential eosinophil transmigration
    Julie B Sedgwick
    Division of Allergy and Immunology, Department of Medicine, University of Wisconsin, Madison, USA
    J Allergy Clin Immunol 110:752-6. 2002
    ....
  32. ncbi Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma
    Linying Liu
    Allergy and Immunology Section, and Pulmonary and Critical Care Section, Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792-9988, USA
    Am J Respir Crit Care Med 169:1118-24. 2004
    ..However, asthma subjects with a dual-responder phenotype have greater generation of chemokines that may lead to enhanced airway inflammation and obstruction after allergen exposure...
  33. ncbi Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge
    Lin Ying Liu
    Allergy and Immunology, Department of Medicine, University of Wisconsin, Madison 53792, USA
    J Immunol 169:6452-8. 2002
    ..These observations provide a potential explanation for the inability of anti-IL-5 therapy to suppress airway hyperresponsiveness to inhaled Ag, despite a reduction in eosinophil recruitment...
  34. ncbi The presence of rhinovirus in lower airways of patients with bronchial asthma
    Monika Wos
    University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Am J Respir Crit Care Med 177:1082-9. 2008
    ..The common cold virus, human rhinovirus (HRV), is the most frequent cause of asthma exacerbations. However, a possible contribution of HRV to the pathogenesis of chronic, persistent asthma has not been defined...
  35. ncbi Comparative effect of body mass index on response to asthma controller therapy
    E Rand Sutherland
    Department of Medicine, National Jewish Health, Denver, Colorado, USA
    Allergy Asthma Proc 31:20-5. 2010
    ..05). FP produced a significantly greater clinical response for normal, overweight, and obese subjects compared with montelukast. Irrespective of BMI, FP appears to be the more effective asthma controller therapy...
  36. ncbi A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma
    Sally E Wenzel
    Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Am J Respir Crit Care Med 179:549-58. 2009
    ..The treatment effect of golimumab, a human monoclonal antibody against tumor necrosis factor (TNF)-alpha, in severe persistent asthma is unknown...
  37. ncbi A comparison of the airway response to segmental antigen bronchoprovocation in atopic asthma and allergic rhinitis
    Elizabeth A Becky Kelly
    Pulmonary and Critical Care Section of the Department of Medicine, University of Wisconsin, Madison 53792, USA
    J Allergy Clin Immunol 111:79-86. 2003
    ....
  38. ncbi Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis
    William W Busse
    University of Wisconsin, Madison, WI, USA
    Curr Med Res Opin 23:2379-86. 2007
    ..We investigated the effect of omalizumab on asthma outcomes in a retrospective pooled analysis of data from phase III clinical trials in patients (>or= 12 years) with moderate-to-severe persistent IgE-mediated allergic asthma...
  39. ncbi Ligation of intercellular adhesion molecule 3 inhibits GM-CSF production by human eosinophils
    Julie M Kessel
    Departments of Pediatrics and Medicine, University of Wisconsin Medical School, Madison, WI 53792 4108, USA
    J Allergy Clin Immunol 111:1024-31. 2003
    ..Intercellular adhesion molecule 3 (ICAM-3) has recently been identified on the surface of eosinophils...
  40. ncbi Expression of interleukin-5- and granulocyte macrophage-colony-stimulating factor-responsive genes in blood and airway eosinophils
    Mary E Bates
    Department of Biomolecular Chemistry, University of Wisconsin, 1300 University Ave, Madison, WI 53706, USA
    Am J Respir Cell Mol Biol 30:736-43. 2004
    ..e., lymphotoxin beta and CD24). These studies have identified several transcriptional targets of IL-5 and GM-CSF in human eosinophils and suggest that a number of protein products are critical to the responsiveness of airway eosinophils...
  41. ncbi Comparison of the effects of repetitive low-dose and single-dose antigen challenge on airway inflammation
    Lin-Ying Liu
    Allergy and Immunology Section of the Department of Medicine, University of Wisconsin Hospital, Madison, USA
    J Allergy Clin Immunol 111:818-25. 2003
    ..Moreover, our limited data also suggest that immunologic tolerance might be induced by frequent challenges...
  42. ncbi Host immune responses to rhinovirus: mechanisms in asthma
    John T Kelly
    Section of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Allergy Clin Immunol 122:671-82; quiz 683-4. 2008
    ..Therefore, understanding the immune response to rhinovirus is a key step in defining mechanisms of asthma, exacerbations, and, perhaps most importantly, improved treatment...
  43. ncbi Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation
    Melissa A Rosenkranz
    Department of Psychology, Laboratory for Affective Neuroscience, University of Wisconsin, 1202 West Johnson Street, Madison, WI 53706, USA
    Proc Natl Acad Sci U S A 102:13319-24. 2005
    ....
  44. ncbi Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
    W Busse
    Department of Medicine, University of Wisconsin Hospital and Clinics, University of Wisconsin, Madison, 53792, USA
    J Allergy Clin Immunol 108:184-90. 2001
    ..CONCLUSION: The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use...
  45. ncbi Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge
    Mats W Johansson
    Department of Biomolecular Chemistry, University of Wisconsin, Madison, WI53706, USA
    J Immunol 180:7622-35. 2008
    ..Finally, eosinophils present in IL-5-rich airway fluid have a hyperadhesive phenotype associated with increased surface expression of alpha(M)beta(2) and activation of beta(2) integrins...
  46. ncbi Short-term safety of somatropin inhalation powder in adults with mild to moderate asthma
    Harold S Nelson
    Department of Medicine, National Jewish Health, Denver, Colorado 80206, USA
    Allergy Asthma Proc 30:325-32. 2009
    ..Future studies of SIP may enroll subjects with mild to moderate asthma for longer-term evaluation of safety and efficacy...
  47. ncbi Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha
    Lin Ying Liu
    Section of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine, Madison, WI 53792, USA
    J Immunol 179:4840-8. 2007
    ....
  48. ncbi Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation
    Ronald L Sorkness
    Univ of Wisconsin, 777 Highland Ave, Madison, WI 53705, USA
    J Appl Physiol 104:394-403. 2008
    ..We conclude that air trapping is a characteristic feature of the severe asthma population, suggesting that there is a pathological process associated with severe asthma that makes airways more vulnerable to this component...
  49. ncbi Age-related changes in eosinophil function in human subjects
    Sameer K Mathur
    Section of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, K4 910 Clinical Sciences Center, 600 Highland Ave, Madison, WI 53792, USA
    Chest 133:412-9. 2008
    ..We sought to define age-related changes in eosinophil function and their potential implications for asthma...
  50. ncbi Asthma: clinical expression and molecular mechanisms
    Robert F Lemanske
    Department of Pediatrics, University of Wisconsin Medical School, Madison, Wis, USA
    J Allergy Clin Immunol 125:S95-102. 2010
    ..This review will highlight some of the important clinical features of asthma and emphasize recent advances in both pathophysiology and treatment...
  51. ncbi Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16
    Jennifer P DeMore
    Department of Medicine, University of Wisconsin Madison, Madison, Wis, USA
    J Allergy Clin Immunol 124:245-52, 252.e1-3. 2009
    ..Rhinovirus infections are frequent causes of asthma exacerbations...
  52. ncbi Evaluation of structure-function relationships in asthma using multidetector CT and hyperpolarized He-3 MRI
    Sean B Fain
    Department of Medical Physics, University of Wisconsin, Madison, WI 53792, USA
    Acad Radiol 15:753-62. 2008
    ....
  53. ncbi Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control
    Loren C Denlinger
    Section of Allergy, Pulmonary, and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, P O Box 9988, Madison, WI 53792, USA
    Am J Respir Crit Care Med 179:265-70. 2009
    ..Upper respiratory tract infection is a guideline accepted risk domain for the loss of asthma control. The ionotrophic nucleotide receptor P2X(7) regulates compartmentalized acute inflammation and the immune response to airway pathogens...
  54. ncbi Ligation of intercellular adhesion molecule 3 induces apoptosis of human blood eosinophils and neutrophils
    Julie M Kessel
    Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, WI 53715, USA
    J Allergy Clin Immunol 118:831-6. 2006
    ..Intercellular adhesion molecule 3 (ICAM-3) is highly expressed on human granulocytes, including eosinophils and neutrophils, but the functions of ICAM-3 in these cells are not well understood...
  55. ncbi Serum and low-density lipoprotein enhance interleukin-8 secretion by airway epithelial cells
    James E Gern
    Department of Pediatrics, University of Wisconsin Madison, Madison, WI 53792 9988, USA
    Am J Respir Cell Mol Biol 29:483-9. 2003
    ..This effect may represent an innate mechanism for the recruitment of neutrophils to the airway in response to noxious stimuli, such as viral infections, that increase vascular permeability...
  56. ncbi 6. Asthma: Factors underlying inception, exacerbation, and disease progression
    Robert F Lemanske
    Departments of Pediatrics and Medicine, University Hospital, University of Wisconsin Medical School, 600 Highland Avenue K4 916, Madison, WI 43792, USA
    J Allergy Clin Immunol 117:S456-61. 2006
    ..Unfortunately, despite the availability of effective therapies, suboptimal asthma control exists in many patients on a worldwide basis. The future development of novel therapies and treatment paradigms should address these disparities...
  57. ncbi Oxidized low-density lipoprotein activates migration and degranulation of human granulocytes
    Julie B Sedgwick
    University of Wisconsin, H6 355 CSC 3244 600 Highland Ave, Madison, WI 53792, USA
    Am J Respir Cell Mol Biol 29:702-9. 2003
    ..05). Therefore, in vivo influx and oxidation of LDL may be an important mediator for the initiation of bronchial inflammation where granulocytes are recruited to the lung...
  58. ncbi Rhinovirus-induced interferon-gamma and airway responsiveness in asthma
    G Daniel Brooks
    Departments of Medicine and Pediatrics, University of Wisconsin, Madison, Wisconsin, USA
    Am J Respir Crit Care Med 168:1091-4. 2003
    ....
  59. ncbi Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions
    Julie B Sedgwick
    Allergy and Immunology Unit, Department of Medicine, University of Wisconsin, Madison, WI, USA
    J Allergy Clin Immunol 116:812-9. 2005
    ..Small-molecule VLA-4 antagonists have been proposed as a therapeutic mechanism to prevent eosinophil infiltration in asthma; however, they might affect other eosinophil functions...
  60. ncbi The role of rhinovirus in asthma exacerbations
    Samuel L Friedlander
    Division of Allergy and Immunology, Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    J Allergy Clin Immunol 116:267-73. 2005
    ..Advances in our understanding of this interaction might provide knowledge that could ultimately lead to specific treatment modalities to prevent and/or treat this significant burden of asthma exacerbations...
  61. ncbi Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues
    Anne G Mosser
    University of Wisconsin, K4 928 CSC 9988, 600 Highland Avenue, Madison, WI 53792, USA
    Am J Respir Crit Care Med 171:645-51. 2005
    ..These results confirm that infection of lower airway tissues is a frequent finding during a cold and further demonstrate a patchy distribution of infected cells, a pattern similar to that reported in upper airway tissues...
  62. ncbi Peripheral blood eosinophils from patients with allergic asthma contain increased intracellular eosinophil-derived neurotoxin
    Julie B Sedgwick
    Allergy and Immunology, Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    J Allergy Clin Immunol 114:568-74. 2004
    ....
  63. ncbi Double-stranded RNA induces the synthesis of specific chemokines by bronchial epithelial cells
    James E Gern
    Department of Pediatrics, University of Wisconsin Madison Medical School, Madison, Wisconsin, USA
    Am J Respir Cell Mol Biol 28:731-7. 2003
    ..Moreover, these data suggest that this may be an important mechanism for the selective secretion of chemokines by viruses (e.g., rhinovirus, respiratory syncytial virus, influenza) that synthesize dsRNA during replication...
  64. ncbi Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma
    William W Busse
    University of Wisconsin School of Medicine and Public Health, Madison, Wis, USA
    J Allergy Clin Immunol 125:1237-1244.e2. 2010
    ..IL-5 is responsible for eosinophil differentiation, proliferation, and activation; IL-5 receptors are expressed on eosinophils and their progenitors, and targeting such receptors induces eosinophil apoptosis...
  65. ncbi Relationship of viral infections to wheezing illnesses and asthma
    James E Gern
    Department of Pediatrics, University of Wisconsin Hospital, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Nat Rev Immunol 2:132-8. 2002
    ..This article discusses the influence of viral infections on mechanisms of virus-induced airway inflammation in relationship to the development, persistence and severity of asthma...
  66. ncbi Similar frequency of rhinovirus-infectible cells in upper and lower airway epithelium
    Anne G Mosser
    Department of Medicine, Division of Allergy and Immunology, University of Wisconsin, Madison, Wisconsin 53792, USA
    J Infect Dis 185:734-43. 2002
    ..In confirming that RV can infect cells in the lower airway, these results suggest that lower airway dysfunction occurs through this mechanism in susceptible persons...
  67. ncbi 6. Asthma
    Robert F Lemanske
    Departments of Medicine and Pediatrics, University of Wisconsin Medical School, Madison, WI 53792, USA
    J Allergy Clin Immunol 111:S502-19. 2003
    ....
  68. ncbi Advances in mechanisms of allergy
    Bruce S Bochner
    Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Room 2B.71, Baltimore, MD 21224-6801, USA
    J Allergy Clin Immunol 113:868-75. 2004
    ..When appropriate, articles from other journals have been included to supplement the topics being presented...
  69. ncbi Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge
    Lin Ying Liu
    Allergy and Immunology Section, Department of Medicine, University of Wisconsin, Madison, WI 53972, USA
    J Allergy Clin Immunol 112:556-62. 2003
    ..These changes in chemokine receptors could be involved in determining eosinophil function and antigen-induced airway inflammation...
  70. ncbi Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process
    Lin Ying Liu
    Allergy and Immunology, Department of Medicine, University of Wisconsin, Madison 53792, USA
    J Immunol 169:6459-66. 2002
    ..These findings suggest that IL-5-activated eosinophils may lose mIL-5Ralpha and release sIL-5Ralpha in vivo, which may limit IL-5-dependent inflammatory events in diseases such as asthma...
  71. ncbi Human rhinovirus models in asthma
    Anne Marie Singh
    Department of Medicine, University of Wisconsin Medical School, Madison, WI 53792, USA
    Contrib Microbiol 14:12-20. 2007
    ..Work further investigating the mechanisms of exacerbation caused by RV infection will ultimately lead to new modalities of treatment and possibly prevention of this common and significant cause of acute asthma...
  72. ncbi Asthma: diagnosis and management
    Sameer K Mathur
    Section of Allergy, Pulmonary, and Critical Care, Department of Medicine, University of Wisconsin Medical School, Madison, WI 53792, USA
    Med Clin North Am 90:39-60. 2006
    ....
  73. ncbi Three-dimensional imaging of ventilation dynamics in asthmatics using multiecho projection acquisition with constrained reconstruction
    James H Holmes
    Department of Medical Physics, University of Wisconsin Madison, Madison, Wisconsin, USA
    Magn Reson Med 62:1543-56. 2009
    ..While multidetector CT can provide information about static regional air trapping, it is unable to depict dynamics in a setting more comparable to a spirometry maneuver and explore the longitudinal time evolution of the trapped regions...
  74. ncbi Refractory asthma
    Maureen McGeehan
    Department of Medicine, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Med Clin North Am 86:1073-90. 2002
    ..Unfortunately, most alternative approaches require more rigorous evidence to support their regular use...
  75. ncbi Asthma
    Saju S Eapen
    University of Wisconsin Medical School, Madison, Wisconsin, USA
    Clin Allergy Immunol 16:325-53. 2002
    ..Enhanced knowledge of molecular and cellular events in the inflammatory process would inevitably lead to newer, more specific, therapeutic agents, which would potentially be curative rather than palliative...
  76. ncbi Is interleukin-10 a "10" in virus-provoked asthma?
    William W Busse
    Am J Respir Crit Care Med 172:405-6. 2005
  77. ncbi Severe asthma: lessons from the Severe Asthma Research Program
    Sally E Wenzel
    University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    J Allergy Clin Immunol 119:14-21; quiz 22-3. 2007
    ..Future studies will specifically evaluate the role of inflammatory/oxidative processes, infection, genetics, and the distal lung in the pathogenesis of severe asthma...
  78. ncbi Who is captain of the inflammatory ship in asthma?
    Elizabeth A B Kelly
    Am J Respir Crit Care Med 169:551-2. 2004
  79. ncbi Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial
    Stanley J Szefler
    National Jewish Health, Denver, CO, USA
    Lancet 372:1065-72. 2008
    ....
  80. ncbi Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
    Romain A Pauwels
    Department of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium
    Lancet 361:1071-6. 2003
    ..Although inhaled glucocorticosteroids are recommended for persistent asthma, their long-term effect on recent onset, mild, persistent asthma has yet to be established...
  81. ncbi Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma
    Ratko Djukanovic
    Respiratory Cell and Molecular Biology, Division of Infection, Inflammation, and Repair, University of Southampton, Southampton, UK
    Am J Respir Crit Care Med 170:583-93. 2004
    ..The lack of effect of omalizumab on methacholine responsiveness suggests that IgE or eosinophils may not be causally linked to airway hyperresponsiveness to methacholine in mild to moderate asthma...
  82. ncbi Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study
    Eric D Bateman
    UCT Lung Institute, P O Box 34560, Groote Schuur 7937, Cape Town, South Africa
    Am J Respir Crit Care Med 170:836-44. 2004
    ..07-0.27 per patient per year) and improvement in health status were significantly better with salmeterol/fluticasone. This study confirms that the goal of guideline-derived asthma control was achieved in a majority of the patients...
  83. ncbi Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
    Wendy C Moore
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:405-13. 2007
    ..Severe asthma causes the majority of asthma morbidity. Understanding mechanisms that contribute to the development of severe disease is important...
  84. ncbi Severe asthma in adults: what are the important questions?
    Pascal Chanez
    INSERM U454 and Clinique des Maladies Respiratoires, Montpellier, France
    J Allergy Clin Immunol 119:1337-48. 2007
    ..Inhaled corticosteroids and bronchodilators are the mainstay of treatment, but patients with SRA remain uncontrolled, indicating a need for new therapies...
  85. ncbi Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma
    Paul M O'Byrne
    Department of Medicine, McMaster University Medical Center, 1200 Main St West, Hamilton, ON, Canada
    Chest 129:1478-85. 2006
    ..Asthmatic patients lose lung function faster than normal subjects. The effectiveness of early intervention with inhaled corticosteroids on this decline in lung function is not established in recent-onset disease...
  86. ncbi Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study
    Søren E Pedersen
    Department of Pediatrics, University of Southern Denmark, Pediatric Research Unit, Kolding Hospital, Kolding, Denmark
    J Allergy Clin Immunol 120:1036-42. 2007
    ..Approximately two thirds of patients achieved well-controlled (WC) asthma, and one third continued to have asthma that was not well controlled (NWC)...
  87. ncbi Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study
    Eric D Bateman
    University of Cape Town, Cape Town, South Africa
    J Asthma 44:667-73. 2007
    ....
  88. ncbi Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines
    Allan R Brasier
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 1060, USA
    J Allergy Clin Immunol 121:30-37.e6. 2008
    ..Asthma is a heterogeneous clinical disorder. Methods for objective identification of disease subtypes will focus on clinical interventions and help identify causative pathways. Few studies have explored phenotypes at a molecular level...
  89. ncbi Eosinophil beta 1 integrin activation state correlates with asthma activity in a blind study of inhaled corticosteroid withdrawal
    Mats W Johansson
    J Allergy Clin Immunol 117:1502-4. 2006
  90. ncbi The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking
    Daniel L Venarske
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37230-8300 USA
    J Infect Dis 193:1536-43. 2006
    ..Compared with hospitalized patients with asthma who were RV negative, RV-positive patients were significantly more likely to be smokers and nonusers of ICSs...
  91. ncbi Early intervention of recent onset mild persistent asthma in children aged under 11 yrs: the Steroid Treatment As Regular Therapy in early asthma (START) trial
    Yu Zhi Chen
    Department of Pediatrics, Capital Institute of Pediatrics, Beijing, China
    Pediatr Allergy Immunol 17:7-13. 2006
    ....
  92. ncbi Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma
    Jill P Karpel
    Albert Einstein College of Medicine, Beth Thalheim Asthma Center, North Shore Long Island Jewish Health System, New Hyde Park, NY 11040, USA
    Ann Pharmacother 39:1977-83. 2005
    ..The chronobiology of asthma suggests that, for once-daily dosing, an evening dose may be the most effective treatment paradigm...
  93. ncbi Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma
    Anna Planagumà
    Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Respir Crit Care Med 178:574-82. 2008
    ..Airway inflammation is common in severe asthma despite antiinflammatory therapy with corticosteroids. Lipoxin A(4) (LXA(4)) is an arachidonic acid-derived mediator that serves as an agonist for resolution of inflammation...
  94. ncbi Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids
    Anthony D'Urzo
    Primary Care Lung Clinic, Toronto, Ontario, Canada
    Curr Med Res Opin 21:1281-9. 2005
    ..Since asthma is frequently worse at night, evening dosing appears to be a more obvious choice to accommodate the chronobiology of asthma than morning dosing...
  95. ncbi Investigative bronchoprovocation and bronchoscopy in airway diseases
    William W Busse
    University of Wisconsin-Madison, USA
    Am J Respir Crit Care Med 172:807-16. 2005
    ..CONCLUSION: This review of investigative bronchoscopy and bronchoprovocation could serve as the basis for future guidelines for the use of these procedures in the United States...
  96. ncbi Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma
    Suzy A A Comhair
    Department of Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Respir Crit Care Med 172:306-13. 2005
    ....
  97. ncbi Effectiveness of early budesonide intervention in Caucasian versus Asian patients with asthma: 3-year results of the START study
    Wan C Tan
    iCAPTURE Centre, UBC, St Paul s Hospital, Vancouver, and Department of Medicine, McMaster University, Hamilton, ON, Canada
    Respirology 11:767-75. 2006
    ..The present analysis compared the efficacy of early intervention with inhaled budesonide in Caucasian and Asian patients over the first 3 years of the inhaled Steroid Treatment As Regular Therapy in early asthma study...

Research Grants16

  1. Severe Asthma From Respiratory Infections
    William W Busse; Fiscal Year: 2010
    ..These studies will provide new insights into the mechanisms of asthma, particularly severe disease, and possibilities of new approaches to treatment. ..
  2. Severe Asthma From Respiratory Infections
    William Busse; Fiscal Year: 2005
    ..It is proposed that these studies will provide new insights into mechanisms of asthma, and particularly severe persistent disease, and potential new approaches to treatment. ..
  3. MECHANISMS OF RHINOVIRUS INDUCED ASTHMA
    William Busse; Fiscal Year: 2002
    ..The proposed studies will provide new evidence as the mechanisms by which RV-infected epithelial cells cause granulocytic bronchial inflammation and asthma exacerbations. ..
  4. Severe Asthma From Respiratory Infections
    William Busse; Fiscal Year: 2009
    ..These studies will provide new insights into the mechanisms of asthma, particularly severe disease, and possibilities of new approaches to treatment. ..